Overall survival. (A) OS of the entire cohort without a significant difference in OS after allo-HSCT in LAD-I vs LAD-III (P = .770). (B) Patients receiving a graft from MSD or 10/10 MD were similar in their OS and were significanlty superior to other donor types (P = .001).